ArticleAmerican journal of translational research2023
Mechanisms of MALAT1 regulating proliferative diabetic retinopathy via targeting miR-126-5p.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 6 citations in OpenAlex.
- Endothelial cell heterogeneity drives angiogenesis in endometriosis: mechanisms and emerging organoid-based models.Apoptosis : an international journal on programmed cell death · 2026Review
- miR-501-5p mediates the progression of type 2 diabetic retinopathy by targeting NR2F2.Diabetology & metabolic syndrome · 2026Article
- Exploring the role of miR-126 in diabetes and its complications: a comprehensive review.Diabetology & metabolic syndrome · 2025Review
- Review
- Dysregulation of long non-coding RNA gene expression pathways in monocytes of type 2 diabetes patients with cardiovascular disease.Cardiovascular diabetology · 2024Article
- A novel long non-coding RNA XLOC_004787, is associated with migration and promotes cancer cell proliferation by downregulating mir-203a-3p in gastric cancer.BMC gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveDiabetic retinopathy (DR) is the primary reason for blindness among the middle-aged and elderly. It can progress to proliferative diabetic retinopathy (PDR), a condition that is accompanied by retinal neovascularization as the disease worsens. Understanding the pathogenesis of PDR can facilitate the development of treatments. In this study, we aimed to investigate the involvement in the lncRNA MALAT1 (MALAT1)/miR-126-5p axis in modulating PDR progression.
methodsRat retinal endothelial cells (RECs) was induced with 30 mM glucose to build an
resultsIn high-glucose induced RECs, MALAT1 was up-regulated while miR-126-5p was down-regulated. The angiogenesis as well as the proliferation and migration capacities of high glucose-induced RECs were suppressed when MALAT1 was down-regulated or miR-126-5p was up-regulated, accompanied by reductions in VEGF, MMP-2 and MMP9. RNA immunoprecipitation assay confirmed that miR-126-5p could be enriched in MALAT1 sequences. Dual-luciferase reporter assay confirmed the targeted inhibition of miR-126-5p by MALAT1. Downregulating miR-126-5p counteracted the effect of MALAT1 downregulation on RECs induced by high glucose.
conclusionsMALAT1 promotes PDR by inhibiting miR126-5p and inducing REC proliferation, migration and angiogenesis.
Indexed as
Identifiers
37303661PMC10251023W4380290910What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.